Catalog Advanced Search
-
Contains 1 Component(s)
Hosted live on November 1, 2023 by the MASLD SIG.
The nomenclature change from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) marks a significant advancement in liver disease understanding as it recognizes the role of metabolic factors beyond fat accumulation in liver disease. The webinar will delve into the rationale and purpose of this shift in nomenclature in its ability to foster interdisciplinary collaboration, enhance public health initiatives, and drive focused research in the various phenotypes within steatotic liver diseases for improved patient outcomes. Embracing MASLD heralds a future of effective liver disease management including pharmacologic and non-pharmacologic intervention(s) and empowers healthcare professionals to better understand and manage the disease.
Our audience will gain a better understanding of the rationale behind the nomenclature change in steatotic liver disease classification, specifically on the evolving evidence and concepts in liver disease pathophysiology that necessitated the shift in nomenclature. Emphasis will be placed on the clinical application of the new classification, exploring how it enables more accurate diagnoses and tailored interventions for patients. Lastly, its potential implications for future research and pharmacologic development, showcasing its role in advancing the field and improving patient outcomes.
-
Contains 1 Component(s)
Webinar originally aired 10/03/2023
Novel emerging topics in understanding pivotal mechanisms in NASH development and progression to fibrosis. The focus will be on contribution and mechanisms of immune cells and organ/cell crosstalk in NASH development leading to therapeutic targets.
-
Contains 1 Component(s)
Hosted by AASLD's Portal Hypertension SIG. This webinar will explore the new field of endohepatology.
Originally presented on September 13, 2023.
Attendees will learn about the endoscopic techniques that are now being applied to the diagnosis and management of patients with liver disease.
Moderator: Don Rockey, MD
Speakers:
Reem Sharaiha, MD | Zachary Henry, MD | Theo Heller, MD
-
Contains 1 Component(s)
This will be a single lecture reviewing the differential diagnosis of AKI, including a focus on AKI-HRS, and then review management strategies. There will be focus on terlipressin given its the publication of the recent NA RCT and its FDA approval, including indications, contraindications, and potential side effects (including the important pulmonary side effects).
This will be a single lecture reviewing the differential diagnosis of AKI, including a focus on AKI-HRS, and then review management strategies. There will be focus on terlipressin given its the publication of the recent NA RCT and its FDA approval, including indications, contraindications, and potential side effects (including the important pulmonary side effects).
Originally presented on July 20th, 2023
Presenters: Pratima Sharma, University of Michigan
Moderator: Florence Wong, University of Toronto -
Contains 1 Component(s)
During this webinar, attendees will learn about mechanistic studies and treatment options for fatigue in autoimmune liver diseases as well as mechanistic studies and treatment options for pruritus in autoimmune liver diseases.
During this webinar, attendees will learn about mechanistic studies and treatment options for fatigue in autoimmune liver diseases as well as mechanistic studies and treatment options for pruritus in autoimmune liver diseases.
Originally presented on July 11, 2023
Moderator: Michele M Tana, MD | Mitchell Mah Moud, MD
Presenters: Mark Swain, MD | Andreas Kremer, MD | Gideon Hirschfield, MDHosted by Cholestatic and Autoimmune Liver Diseases SIG
-
Contains 1 Component(s)
Sexual and gender minorities people often face discrimination and harassment due to their sexual orientation and gender identity, and this population has been identified as at risk for "health disparity" by the National Institute on Minority Health and Health Disparities. The hepatology care of transgender and gender non-binary people can be complicated, given the involvement of gender-affirming therapy, psychosocial stress, and even legal challenges. In this session, we will discuss basic knowledge about transgender patients and how to provide the best hepatology care for them.
Sexual and gender minorities people often face discrimination and harassment due to their sexual orientation and gender identity, and this population has been identified as at risk for "health disparity" by the National Institute on Minority Health and Health Disparities. The hepatology care of transgender and gender non-binary people can be complicated, given the involvement of gender-affirming therapy, psychosocial stress, and even legal challenges. In this session, we will discuss basic knowledge about transgender patients and how to provide the best hepatology care for them.
Originally presented on June 28th, 2023Presenters: Howard T. Lee, Baylor College of Medicine | Elizabeth Goacher, Duke University Medical Center | Sonali Paul, University of Chicago
Moderator: Howard T. Lee, Baylor College of Medicine | Elizabeth Goacher, Duke University Medical Center -
Contains 1 Component(s)
This webinar is part two of a two-part series which focuses on the evaluation of donors and recipients for complex LDLT cases with input from hepatology, surgery, the living donor, and the recipient. Attendees of this webinar will gain the unique perspective of the considerations at play when determining the suitability of a donor and a recipient for a complex living donor liver transplant procedure. Additionally, attendees will gain a better understand of the patient perspective of being evaluated to be a living donor, being considered as a recipient of a living donor liver transplant, and the post-donation course from a prior living liver donor and her recipient.
This webinar is part two of a two-part series which focuses on the evaluation of donors and recipients for complex LDLT cases with input from hepatology, surgery, the living donor, and the recipient. Attendees of this webinar will gain the unique perspective of the considerations at play when determining the suitability of a donor and a recipient for a complex living donor liver transplant procedure. Additionally, attendees will gain a better understand of the patient perspective of being evaluated to be a living donor, being considered as a recipient of a living donor liver transplant, and the post-donation course from a prior living liver donor and her recipient.
Originally presented on June 8th, 2023Presenters: Benjamin Samstein, MD | Deborah Bandaruk | Kimberly Schadt
Moderator: David Goldberg, MD -
Contains 1 Component(s)
This webinar is part one of a two-part series which features a hepatologist and a surgeon who helped to build and expand their center's living donor liver transplant programs. Attendees of this webinar will gain a greater understanding of how to build and sustain a high-volume living donor liver transplant program from the perspective of a hepatologist and a transplant surgeon who each helped to grow their respective living donor programs.
This webinar is part one of a two-part series which features a hepatologist and a surgeon who helped to build and expand their center's living donor liver transplant programs. Attendees of this webinar will gain a greater understanding of how to build and sustain a high-volume living donor liver transplant program from the perspective of a hepatologist and a transplant surgeon who each helped to grow their respective living donor programs.
Originally presented on May 31st, 2023.Presenters: Kiran Bambha, MD, MSc | Abhinav Humar, MD
Moderator: Pratima Sharma, MD -
Contains 1 Component(s)
Globally, alcohol-associated liver disease (ALD) accounts for 50% of liver-related deaths and is the leading indication for liver transplantation (Lee BP et al JAMA Med 2020). Abstinence from alcohol is the strongest predictor of long-term survival in ALD. While evidence-based therapies for AUD exist to increase rates of abstinence and reduce rates of heavy drinking, patients with ALD rarely receive these therapies (Rogal S et al Hepatology 2020). The barriers to accessing AUD therapy among patients with ALD are likely multifactorial. While the hepatology clinic represents a potential opportunity to provide therapy for AUD to improve clinical outcomes, this is rarely done. A recent survey (Im GY et al CGH 2020) commissioned by the AASLD ALD Special Interest Group reported that the majority (71%) hepatology providers never provide behavioral or pharmacotherapy for AUD, with the most common reason being low comfort (84%). Most (77%) reported low addiction education and 90% desired more training. We have developed this webinar proposal to address these clinical gaps by educating our hepatology community and empowering them with the tools to deliver evidence-based interventions for AUD among patients with ALD in their liver clinic. In this AASLD webinar, we provide a very clinically-applicable overview of steps that providers (hepatologists, nurse practitioners, etc.) in a liver clinic can make to address AUD for their patients with ALD. The webinar provides a multi-disciplinary approach, but focuses on what is realistic and practical for an every-day liver clinic, which can have variable resources and patient populations.
Hosted by: ALD SIG
Our target audience may be broad with a mix of healthcare providers, researchers, possibly patients and patient advocates in all parts of the world.
-
Contains 1 Component(s)
Our understanding of “immune tolerance” in chronic hepatitis B has been evolving, with continued debates on their clinical management and treatment. This webinar will help provide updates in broad perspective, scientific context and clinical implications.
Hosted by: Hepatitis B SIG
Our target audience may be broad with a mix of healthcare providers, researchers, possibly patients and patient advocates in all parts of the world. Our understanding of “immune tolerance” in chronic hepatitis B has been evolving, with continued debates on their clinical management and treatment. So, this webinar will help provide updates in broad perspective, scientific context and clinical implications. In this context, our stated learning objectives and expected outcomes are:
Learning Objectives:
Learners will be able to understand the underlying concept and controversies around the definition of immune tolerance, to inform their clinical care and education.
Learners will be able to apply these concepts to clinical monitoring, therapeutic decisions and patient education.
Expected program outcome:
Promote further open dialogue among international hepatology community regarding mechanisms and significance of apparent immune tolerance in HBV-infected patients
Increased scientific activities and knowledge with collaborations and funding on this topic
